Neuberger Berman Group LLC Has $243.95 Million Stock Holdings in Becton Dickinson and Co (NYSE:BDX)

Neuberger Berman Group LLC trimmed its holdings in Becton Dickinson and Co (NYSE:BDX) by 8.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,020,435 shares of the medical instruments supplier’s stock after selling 99,333 shares during the quarter. Neuberger Berman Group LLC owned about 0.35% of Becton Dickinson and worth $243,949,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in Becton Dickinson and by 225.4% during the 1st quarter. Wellington Management Group LLP now owns 8,473,220 shares of the medical instruments supplier’s stock worth $1,946,892,000 after purchasing an additional 5,869,236 shares during the last quarter. FMR LLC raised its stake in shares of Becton Dickinson and by 35.7% during the 2nd quarter. FMR LLC now owns 12,360,686 shares of the medical instruments supplier’s stock worth $2,957,540,000 after purchasing an additional 3,253,254 shares in the last quarter. BlackRock Inc. raised its stake in Becton Dickinson and by 9.2% in the 2nd quarter. BlackRock Inc. now owns 20,760,348 shares of the medical instruments supplier’s stock valued at $4,967,327,000 after acquiring an additional 1,755,896 shares during the period. Flossbach Von Storch AG increased its position in Becton Dickinson and by 334.5% during the 1st quarter. Flossbach Von Storch AG now owns 1,875,063 shares of the medical instruments supplier’s stock worth $430,833,000 after buying an additional 1,443,558 shares during the period. Finally, Mackenzie Financial Corp grew its holdings in shares of Becton Dickinson and by 73.8% during the 1st quarter. Mackenzie Financial Corp now owns 2,652,092 shares of the medical instruments supplier’s stock worth $609,371,000 after purchasing an additional 1,126,373 shares in the last quarter. 84.18% of the stock is owned by institutional investors and hedge funds.

Shares of Becton Dickinson and stock traded down $9.82 during trading on Tuesday, reaching $226.08. The company’s stock had a trading volume of 122,156 shares, compared to its average volume of 1,993,046. The stock has a 50-day moving average price of $255.27 and a two-hundred day moving average price of $247.56. The company has a current ratio of 1.45, a quick ratio of 0.97 and a debt-to-equity ratio of 0.71. Becton Dickinson and Co has a one year low of $197.75 and a one year high of $286.72. The stock has a market capitalization of $68.38 billion, a P/E ratio of 84.86, a price-to-earnings-growth ratio of 2.99 and a beta of 0.85.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.04 by $0.16. Becton Dickinson and had a return on equity of 14.19% and a net margin of 5.30%. The business had revenue of $3.86 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same period in the previous year, the business posted $3.08 earnings per share. The firm’s revenue for the quarter was down 11.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Becton Dickinson and Co will post 9.9 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.40%. Becton Dickinson and’s dividend payout ratio is 27.05%.

Several brokerages recently issued reports on BDX. Barclays raised Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $300.00 target price on the stock in a research report on Thursday, July 9th. Raymond James increased their target price on Becton Dickinson and from $265.00 to $285.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. They noted that the move was a valuation call. UBS Group lifted their price target on Becton Dickinson and from $265.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 10th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating and set a $245.00 price target on the stock. in a research report on Wednesday, May 27th. Finally, Goldman Sachs Group assumed coverage on shares of Becton Dickinson and in a report on Sunday, May 31st. They issued a “buy” rating and a $278.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Hold” and an average price target of $279.47.

In other Becton Dickinson and news, EVP Patrick Kaltenbach sold 1,272 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $260.00, for a total transaction of $330,720.00. Following the completion of the sale, the executive vice president now directly owns 10,340 shares of the company’s stock, valued at approximately $2,688,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.12% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: What is the Beige Book?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with's FREE daily email newsletter.